
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : University of Missouri-Columbia
Deal Size : Undisclosed
Deal Type : Collaboration
AI Proteins Signs Collaborative Research Agreement on Radioligand Therapy
Details : The collaboration aims to advance the use of de novo designed miniproteins for targeted radioligand therapy, labeled with alpha and beta-emitting radionuclides are effective as a cancer theranostic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : University of Missouri-Columbia
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $400.0 million
Deal Type : Collaboration
Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M
Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $400.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration
Vivtex and AI Proteins Collaborate On Oral Biologic Therapies
Details : The collaboration aims to develop oral biologic therapies for inflammatory diseases, leveraging Vivtex’s GI-ORIS™ technology to enhance bioavailability of AI Proteins’ miniproteins.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration
